Cancer Research Technology
Search form
Search
Commercial Partnerships
Home
About
Overview
Our People
Our Network
History
Services
Overview
Project Development
Have an idea?
Commercialisation
Drug Discovery
CRUK Drug Discovery
Clinical Development
CDP
Imaging
Funding
Projects
Overview
Our Pipeline
Licensing Opportunities
Small Molecules
Biological Therapeutics
Enabling Technology
Medical Devices
Biomarkers
Our Start-ups
Research Tools
Research Tools
News and Events
News and Events
Alliance of translational research centres established to accelerate global drug development
Astex Pharmaceuticals Earns $5.4 M Milestone on PhI Trial Initiation of a FGFR Kinase Inhibitor
CRT & ADC Therapeutics join forces on Antibody Drug Conjugates
CRT and Teva Pharmaceuticals Form R&D Alliance for Cancer DNA Damage Response Drugs
CRT, The Institute of Cancer Research and Merck Serono sign WNT licensing deal
CRUK Cambridge Institute Symposium
Cancer Research UK and CRT collaborate with Abcodia to discover and develop tests for cancer
FORMA Therapeutics and CRT to discover cancer drugs targeting deubiquitinating enzymes (DUBs)
New board appointment for CRT
New offices for CRT
"This is a great place to come and do business"
2014 BIO International Convention
2014 Medicinal Chemistry Gordon Research Conference
2014 Year in Review Infographic
2015 BIO International Convention
2016 BIO International Convention
26th EORTC-NCI-AACR SYMPOSIUM
28th EORTC-NCI-AACR Symposium
AACR Annual Meeting
AACR Annual Meeting 2015
AACR Annual Meeting 2016
AACR Annual Meeting 2017
AACR-NCI-EORTC 2015
AUTM 2015 Annual Meeting
AUTM 2016 Annual Meeting
Academic Drug Discovery Workshop
Accelerator Structural Biology Conference 2016
Achilles Therapeutics launched with funds of £13.2 million to develop immunotherapies for cancer
Alchemia announces in-licensing of FAK inhibitors from CRT
Autolus Therapeutics raised $100.8 million
BACIT seeks shareholder approval to commit £20m and join CRT Pioneer Fund as a limited partner
BICYCLE THERAPEUTICS AND CANCER RESEARCH UK NAMED BEST PARTNERSHIP ALLIANCE OF THE YEAR AT 2017 SCRIP AWARDS
BIO-EUROPE SPRING 2016
BIO-Europe Spring 2014
Bio-Europe 2015
Bio-Europe Autumn 2016
Bio-Europe Spring 2017
Bio-Homecoming 2016
BioInvents BI-1206 antibody to enter collaborative Phase I/II trial
BioWednesday: Future Directions in Oncology
Biotech and Money London 2015
Biotechs and the City
CRT Highlighted in the Dowling Review of Business-University Research Collaborations
CRT Pioneer Fund banks £20m investment from BACIT and expands agreement with Chroma Therapeutics
CRT Pioneer Fund collaborates with Chroma Therapeutics
CRT Pioneer Fund, BACIT and Sareum enter agreement
CRT Pioneer Fund, Cancer Research UK and NCI collaborate to boost research against the ‘undruggable’ RAS
CRT and Alta Innovations join forces to commercialise world-leading research
CRT and AstraZeneca expand successful multi-project cancer metabolism alliance
CRT and BioInvent expand collaboration with University of Southampton scientists
CRT and SV life sciences form Artios Pharma to focus on DNA damage response
CRT and Teva’s collaboration yields successful outcome with novel aPKC protein inhibitor cancer drug discovery candidate
CRT and The ICR enter collaboration with Janssen to discover multiple myeloma drug
CRT and University of Copenhagen announce agreement with ADC Therapeutics to develop antibody treatments for cancer
CRT and University of Manchester receive success payment from GlaxoSmithKline for cancer epigenetics research collaboration
CRT announces license agreement with MSD to develop inhibitors of PRMT5 for cancer and blood disorders
CRT drives novel and collaborative drug discovery in areas of "hot" cancer science
CRT signs agreement with CiMass for the development of a monoclonal antibody in the treatment of cancer.
CRT unveils screen test for potential drugs to treat oestrogen positive breast cancer
CRT, University of Manchester and GlaxoSmithKline work together to generate new cancer drugs
CRT’s Discovery Laboratories extends alliance with Merck to develop new cancer drugs
CRUK, CRT and Asterias Biotherapeutics partner to trial immunotherapy vaccine for lung cancer
Call for Small Molecules as Tool Compounds
Cancer Advance Harvard Med
Cancer Drug Discovery and Preclinical Development Summit
Cancer Research Technology Pioneer Fund announces investment in blood cancer drugs
Cancer Research Technology and FORMA Therapeutics: An excellent marriage
Cancer Research Technology and Medivir collaborate to develop new class of cancer drugs
Cancer Research Technology and Nuevolution sign multi-target deal to seek potential cancer drugs
Cancer Research Technology and Pangaea Biotech sign license agreement for new cancer drugs
Cancer Research Technology appoints Deborah Harland as Non-Executive Director
Cancer Research Technology introduces Ximbio, an online reagents portal
Cancer Research Technology, UCL, and Tusk Therapeutics join forces to develop cancer immunotherapies
Cancer Research UK AND Bicycle Therapeutics have collaborated to trial new therapy for advanced solid tumours
Cancer Research UK and AstraZeneca launch world class Functional Genomics Centre
Cancer Research UK and AstraZeneca sign deal to repurpose asthma drug that could fight kidney cancer
Cancer Research UK and Cancer Research Technology announce partnership with Monopar Therapeutics
Cancer Research UK and Cancer Research Technology join forces with Astellas on autophagy to find new cancer treatments
Cancer Research UK and Cancer Research Technology partner with TYG Oncology to develop next generation cancer vaccine
Cancer Research UK and Leukaemia & Lymphoma Research team up to boost blood cancer trials
Cancer Research UK and MedImmune establish joint CRUK-MEDI Alliance Laboratory to develop new biologic cancer medicines
Cancer Research UK and MedImmune launch ground-breaking biotherapeutics research centre in Cambridge
Cancer Research UK and Newcastle University extend successful multi-project drug discovery alliance with Astex Pharmaceuticals
Cancer Research UK and the Institute of Cancer Research, London, join forces with Merck in new drug discovery alliance
Cancer Research UK announces drug discovery collaboration with Celgene Corporation
Cancer Research UK brings commercialisation arm in-house
Cancer Research UK drug launched in its first clinical trial
Cancer Research UK to collaborate with AstraZeneca in screening for new cancer medicines
Cancer Research UK, CRT and Amgen to trial leukaemia immunotherapy drug in other cancers
Cancer Research UK, LifeArc and Ono Pharma form cancer immunotherapy alliance
Cancer Research UK’s interview with The Network for Life Science Executive Leaders
Cancer Research UK’s license and collaboration partner Tusk Therapeutics, is acquired by Roche
Consortium signs deal with Basilea to develop resistance-busting cancer drugs
ELRIG Drug Discovery 2015
FASEB: Lipids and Lipid Regulated Kinases in Cancer
FORMA Therapeutics and CRT form a third virtual company to advance deubiquitination assets
FORMA Therapeutics and CRT form two virtual companies to advance deubiquitination assets
GammaDelta Therapeutics Raises Seed Funding from Abingworth
Glythera licenses novel payload class from Cancer Research UK for the development of next-generation antibody drug conjugates
Highlights from the NCRI Conference 2013
HitGen Announces Collaboration in Drug Discovery
Hitgen and Cancer Research UK’s Manchester Institute enter licence agreement in lung cancer
How we are advancing discoveries to beat cancer
Inivata Completes £31.5 Million ($45M) Series A Fundraising Round
Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests
Inivata completes £39.8 million ($52.6M) series B round
Instinctif Partners hosts Cancer Research Technology event on innovative cancer diagnostics and treatments
International deal to screen potential cancer drugs using DNA 'barcodes'
MAJOR DRUG DISCOVERY FEASIBILITY STUDY WITH MERCK SERONO
MISSION Therapeutics raises £60 million to progress development of novel DUB inhibitors from innovative drug platform
MRC Technology, Cancer Research UK and Cancer Research Technology collaborate to focus on cancer immunotherapies
Merck Ventures Creates New Immuno-Oncology Company iOnctura
Metastasis Workshop 2015
NCRI Cancer Conference 2014
NCRI Cancer Conference 2015
NCRI Cancer Conference 2016
Nemucore Medical Innovations Options Clinical-Stage Aurora Kinase Inhibitor GSK1070916 From CRT
Networking at the Top Luncheon
New collaboration for CAR-T cell immuno-oncology therapy development
New offices for CRT Inc.
ON Helix 2014
PDX Models Workshop 2014
PDX Workshop
Preclinical models network taking shape
ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) from CRT Pioneer Fund
Promising results in Phase 1 trial lead immatics to continue work on vaccine (IMA950) for glioblastoma
R&D alliance restructure presents new DNA damage response partnership opportunities including leading PolQ project
Sachs 15th Annual Biotech in Europe Forum
Scancell and Cancer Research UK collaborate to advance novel cancer immunotherapy into clinical trials
Stemline Therapeutics obtains worldwide rights to novel selective RET inhibitor
Storm Therapeutics secures £12m investment for cancer therapeutics
Success all round for CRUK supported spinouts at the OBN annual awards
Successful completion of the Phase I trial of GSK1070916
Takeda and GammaDelta Therapeutics Announce Collaboration to Advance Tissue-derived gamma delta (γδ) T Cells
The CRT Pioneer Fund and Cancer Research UK’s Manchester Institute nominate cancer drug candidate
The Cancer Research UK Innovation Summit
Three new companies join Cancer Research UK-Abcodia collaboration to identify blood markers for early cancer detection
Tumour analysis following surgery could provide breakthrough in predicting how well cancer patients respond to drug treatment
Two Cancer Research Technology deals shortlisted for leading industry awards
UCL’s Cancer Immunology group publishes on the relevance of CD25 as a target in cancer
Valneva and BliNK Therapeutics confirm launch and funding of BliNK Biomedical
World Pharma Licensing Congress 2014
£50M CRT Pioneer Fund announces invest to develop lung cancer drugs at Cancer Research UK's Manchester Institute
Carrick Therapeutics in-licenses targeted ovarian cancer treatment discovered at the ICR
Careers
Careers
Vacancies
Contact Us
Contact Us
Toggle navigation
CRT
SEARCH
Search form
Search
Home
About
Overview
Our People
Our Network
History
Services
Overview
Project Development
Have an idea?
Commercialisation
Drug Discovery
CRUK Drug Discovery
Clinical Development
CDP
Imaging
Funding
Projects
Overview
Our Pipeline
Licensing Opportunities
Small Molecules
Biological Therapeutics
Enabling Technology
Medical Devices
Biomarkers
Our Start-ups
Research Tools
Research Tools
News and Events
News and Events
Alliance of translational research centres established to accelerate global drug development
Astex Pharmaceuticals Earns $5.4 M Milestone on PhI Trial Initiation of a FGFR Kinase Inhibitor
CRT & ADC Therapeutics join forces on Antibody Drug Conjugates
CRT and Teva Pharmaceuticals Form R&D Alliance for Cancer DNA Damage Response Drugs
CRT, The Institute of Cancer Research and Merck Serono sign WNT licensing deal
CRUK Cambridge Institute Symposium
Cancer Research UK and CRT collaborate with Abcodia to discover and develop tests for cancer
FORMA Therapeutics and CRT to discover cancer drugs targeting deubiquitinating enzymes (DUBs)
New board appointment for CRT
New offices for CRT
"This is a great place to come and do business"
2014 BIO International Convention
2014 Medicinal Chemistry Gordon Research Conference
2014 Year in Review Infographic
2015 BIO International Convention
2016 BIO International Convention
26th EORTC-NCI-AACR SYMPOSIUM
28th EORTC-NCI-AACR Symposium
AACR Annual Meeting
AACR Annual Meeting 2015
AACR Annual Meeting 2016
AACR Annual Meeting 2017
AACR-NCI-EORTC 2015
AUTM 2015 Annual Meeting
AUTM 2016 Annual Meeting
Academic Drug Discovery Workshop
Accelerator Structural Biology Conference 2016
Achilles Therapeutics launched with funds of £13.2 million to develop immunotherapies for cancer
Alchemia announces in-licensing of FAK inhibitors from CRT
Autolus Therapeutics raised $100.8 million
BACIT seeks shareholder approval to commit £20m and join CRT Pioneer Fund as a limited partner
BICYCLE THERAPEUTICS AND CANCER RESEARCH UK NAMED BEST PARTNERSHIP ALLIANCE OF THE YEAR AT 2017 SCRIP AWARDS
BIO-EUROPE SPRING 2016
BIO-Europe Spring 2014
Bio-Europe 2015
Bio-Europe Autumn 2016
Bio-Europe Spring 2017
Bio-Homecoming 2016
BioInvents BI-1206 antibody to enter collaborative Phase I/II trial
BioWednesday: Future Directions in Oncology
Biotech and Money London 2015
Biotechs and the City
CRT Highlighted in the Dowling Review of Business-University Research Collaborations
CRT Pioneer Fund banks £20m investment from BACIT and expands agreement with Chroma Therapeutics
CRT Pioneer Fund collaborates with Chroma Therapeutics
CRT Pioneer Fund, BACIT and Sareum enter agreement
CRT Pioneer Fund, Cancer Research UK and NCI collaborate to boost research against the ‘undruggable’ RAS
CRT and Alta Innovations join forces to commercialise world-leading research
CRT and AstraZeneca expand successful multi-project cancer metabolism alliance
CRT and BioInvent expand collaboration with University of Southampton scientists
CRT and SV life sciences form Artios Pharma to focus on DNA damage response
CRT and Teva’s collaboration yields successful outcome with novel aPKC protein inhibitor cancer drug discovery candidate
CRT and The ICR enter collaboration with Janssen to discover multiple myeloma drug
CRT and University of Copenhagen announce agreement with ADC Therapeutics to develop antibody treatments for cancer
CRT and University of Manchester receive success payment from GlaxoSmithKline for cancer epigenetics research collaboration
CRT announces license agreement with MSD to develop inhibitors of PRMT5 for cancer and blood disorders
CRT drives novel and collaborative drug discovery in areas of "hot" cancer science
CRT signs agreement with CiMass for the development of a monoclonal antibody in the treatment of cancer.
CRT unveils screen test for potential drugs to treat oestrogen positive breast cancer
CRT, University of Manchester and GlaxoSmithKline work together to generate new cancer drugs
CRT’s Discovery Laboratories extends alliance with Merck to develop new cancer drugs
CRUK, CRT and Asterias Biotherapeutics partner to trial immunotherapy vaccine for lung cancer
Call for Small Molecules as Tool Compounds
Cancer Advance Harvard Med
Cancer Drug Discovery and Preclinical Development Summit
Cancer Research Technology Pioneer Fund announces investment in blood cancer drugs
Cancer Research Technology and FORMA Therapeutics: An excellent marriage
Cancer Research Technology and Medivir collaborate to develop new class of cancer drugs
Cancer Research Technology and Nuevolution sign multi-target deal to seek potential cancer drugs
Cancer Research Technology and Pangaea Biotech sign license agreement for new cancer drugs
Cancer Research Technology appoints Deborah Harland as Non-Executive Director
Cancer Research Technology introduces Ximbio, an online reagents portal
Cancer Research Technology, UCL, and Tusk Therapeutics join forces to develop cancer immunotherapies
Cancer Research UK AND Bicycle Therapeutics have collaborated to trial new therapy for advanced solid tumours
Cancer Research UK and AstraZeneca launch world class Functional Genomics Centre
Cancer Research UK and AstraZeneca sign deal to repurpose asthma drug that could fight kidney cancer
Cancer Research UK and Cancer Research Technology announce partnership with Monopar Therapeutics
Cancer Research UK and Cancer Research Technology join forces with Astellas on autophagy to find new cancer treatments
Cancer Research UK and Cancer Research Technology partner with TYG Oncology to develop next generation cancer vaccine
Cancer Research UK and Leukaemia & Lymphoma Research team up to boost blood cancer trials
Cancer Research UK and MedImmune establish joint CRUK-MEDI Alliance Laboratory to develop new biologic cancer medicines
Cancer Research UK and MedImmune launch ground-breaking biotherapeutics research centre in Cambridge
Cancer Research UK and Newcastle University extend successful multi-project drug discovery alliance with Astex Pharmaceuticals
Cancer Research UK and the Institute of Cancer Research, London, join forces with Merck in new drug discovery alliance
Cancer Research UK announces drug discovery collaboration with Celgene Corporation
Cancer Research UK brings commercialisation arm in-house
Cancer Research UK drug launched in its first clinical trial
Cancer Research UK to collaborate with AstraZeneca in screening for new cancer medicines
Cancer Research UK, CRT and Amgen to trial leukaemia immunotherapy drug in other cancers
Cancer Research UK, LifeArc and Ono Pharma form cancer immunotherapy alliance
Cancer Research UK’s interview with The Network for Life Science Executive Leaders
Cancer Research UK’s license and collaboration partner Tusk Therapeutics, is acquired by Roche
Consortium signs deal with Basilea to develop resistance-busting cancer drugs
ELRIG Drug Discovery 2015
FASEB: Lipids and Lipid Regulated Kinases in Cancer
FORMA Therapeutics and CRT form a third virtual company to advance deubiquitination assets
FORMA Therapeutics and CRT form two virtual companies to advance deubiquitination assets
GammaDelta Therapeutics Raises Seed Funding from Abingworth
Glythera licenses novel payload class from Cancer Research UK for the development of next-generation antibody drug conjugates
Highlights from the NCRI Conference 2013
HitGen Announces Collaboration in Drug Discovery
Hitgen and Cancer Research UK’s Manchester Institute enter licence agreement in lung cancer
How we are advancing discoveries to beat cancer
Inivata Completes £31.5 Million ($45M) Series A Fundraising Round
Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests
Inivata completes £39.8 million ($52.6M) series B round
Instinctif Partners hosts Cancer Research Technology event on innovative cancer diagnostics and treatments
International deal to screen potential cancer drugs using DNA 'barcodes'
MAJOR DRUG DISCOVERY FEASIBILITY STUDY WITH MERCK SERONO
MISSION Therapeutics raises £60 million to progress development of novel DUB inhibitors from innovative drug platform
MRC Technology, Cancer Research UK and Cancer Research Technology collaborate to focus on cancer immunotherapies
Merck Ventures Creates New Immuno-Oncology Company iOnctura
Metastasis Workshop 2015
NCRI Cancer Conference 2014
NCRI Cancer Conference 2015
NCRI Cancer Conference 2016
Nemucore Medical Innovations Options Clinical-Stage Aurora Kinase Inhibitor GSK1070916 From CRT
Networking at the Top Luncheon
New collaboration for CAR-T cell immuno-oncology therapy development
New offices for CRT Inc.
ON Helix 2014
PDX Models Workshop 2014
PDX Workshop
Preclinical models network taking shape
ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) from CRT Pioneer Fund
Promising results in Phase 1 trial lead immatics to continue work on vaccine (IMA950) for glioblastoma
R&D alliance restructure presents new DNA damage response partnership opportunities including leading PolQ project
Sachs 15th Annual Biotech in Europe Forum
Scancell and Cancer Research UK collaborate to advance novel cancer immunotherapy into clinical trials
Stemline Therapeutics obtains worldwide rights to novel selective RET inhibitor
Storm Therapeutics secures £12m investment for cancer therapeutics
Success all round for CRUK supported spinouts at the OBN annual awards
Successful completion of the Phase I trial of GSK1070916
Takeda and GammaDelta Therapeutics Announce Collaboration to Advance Tissue-derived gamma delta (γδ) T Cells
The CRT Pioneer Fund and Cancer Research UK’s Manchester Institute nominate cancer drug candidate
The Cancer Research UK Innovation Summit
Three new companies join Cancer Research UK-Abcodia collaboration to identify blood markers for early cancer detection
Tumour analysis following surgery could provide breakthrough in predicting how well cancer patients respond to drug treatment
Two Cancer Research Technology deals shortlisted for leading industry awards
UCL’s Cancer Immunology group publishes on the relevance of CD25 as a target in cancer
Valneva and BliNK Therapeutics confirm launch and funding of BliNK Biomedical
World Pharma Licensing Congress 2014
£50M CRT Pioneer Fund announces invest to develop lung cancer drugs at Cancer Research UK's Manchester Institute
Carrick Therapeutics in-licenses targeted ovarian cancer treatment discovered at the ICR
Careers
Careers
Vacancies
Contact Us
Contact Us
You are here
Home
iOnctura re-sized.jpg
iOnctura re-sized.jpg
